REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Myelodysplastic syndromes (MDS)

Every year, ~10,000 cases of MDS are diagnosed in the United States.2

  • RBC transfusions are required upon diagnosis for approximately 50% of patients with MDS3
  • More than 80% will require RBC transfusions during the course of their disease4

A heterogeneous group of clonal hematopoietic stem cell (HSC) disorders, resulting from acquired genetic or epigenetic aberrations.5–9

  • Peripheral blood cytopenias are a characteristic of MDS. The most common is anemia, followed by neutropenia and thrombocytopenia10
  • Greater than 25% of patients with MDS transform to acute myeloid leukemia (AML), 50% will die from consequences of cytopenias (bleeding, infection, etc.)11

MDS presentation and diagnosis.

Bone Marrow in Del 5q Myelodysplastic Syndromes (MDS)
  • Common cytogenetic abnormality found in MDS
    • Deletion 5q is the most common cytogenetic abnormality found in MDS (~15% of cases)15,16
    • Patients who have deletion 5q can be grouped into 3 distinct categories with variable prognoses: isolated del 5q, del 5q + 1 additional abnormality, and complex abnormalities11,17

Establishing an MDS diagnosis.5

  • History and physical examination
  • Complete blood counts (CBCs), platelets, differential, reticulocyte count
  • Peripheral blood smear
  • Bone marrow biopsy and aspiration
  • Cytogenetics by standard karyotyping
  • Additional laboratory screens*
  • Documentation of transfusion history

  • RBC folate, serum B12, serum erythropoietin, serum ferritin, iron, total iron-binding capacity (TIBC), thyroid-stimulating hormone (TSH), lactate dehydrogenase (LDH).

MDS prognosis.

The International Prognostic Scoring System (IPSS) helps determine prognosis.17

International Prognostic Scoring System (IPSS) Prognosis

The clinical trial for del 5q MDS was an open-label, single-arm, multicenter phase 2 trial (N=148).1

Explore the Trial Design